Link between suicide and asthma drug Singulair

After several reports of suicide, asthma and allergy drug Singulair is being investigated by Health Canada and the FDA for a possible link to mood changes and suicidal behaviour in patients using this drug.

Even though no suicides have been reported in Canada, Health Canada spokesperson Paul Duchesne suggests that patients see their doctors if they have concerns.
Merck has issued a press release where they say that from 11,000 patients enrolled in 40 Singulair trials, none have committed suicide and that FDA advise is not based on clinical studies.